Korean Trial Supports Halving DMARD Doses in Well-Controlled Rheumatoid Arthritis
A randomized South Korean trial found that cutting targeted rheumatoid arthritis drugs to half doses did not worsen disease activity compared with standard dosing over six months. Nearly 90% of patients in both groups maintained low disease activity, meeting the study's noninferiority criteria. The researchers suggest dose tapering may be feasible with careful patient selection and monitoring, but they note that longer-term data are still needed.
The South Korean multicenter study randomized 348 adults with rheumatoid arthritis whose low disease activity had lasted at least six months on targeted DMARDs. Participants averaged 56 years old; most were women, and average disease duration exceeded 11 years. Treatment classes included TNF inhibitors, JAK inhibitors, IL-6 blockade, and abatacept.
Half-dose strategies differed by drug: some patients received smaller amounts per dose, while others had longer intervals, aiming for 50% less exposure. Noninferiority was met, though secondary outcomes sometimes favored standard dosing, and six months may be too brief for definitive conclusions.
If validated longer term, halving targeted RA drug doses could lower medication spending and patient exposure, potentially freeing resources. But patients and clinicians may need closer follow-up to catch flares, and payers might consider tapering policies cautiously. The main societal effect may be a shift toward individualized, monitoring-intensive care rather than uniform dose reduction.